People ask this like it is a lifestyle accessory. It is not. These drugs change appetite circuitry, gastric emptying, and glucose handling hard enough that the average weight loss in modern trials looks like bariatric-adjacent territory for some patients and like an expensive nausea tax for others. The right question is narrower: is chronic obesity disease the diagnosis, is the goal durable cardiometabolic risk reduction, and is the person ready for titration, monitoring, and almost certainly a maintenance phase?

This is general education, not a prescription for any individual.

What actually changed in the evidence

GLP-1 receptor agonists are no longer diabetes shots that also melt weight. Semaglutide 2.4 mg in SELECT cut major adverse cardiovascular events by about 20% in people with overweight or obesity and established heart disease who did not have diabetes. That is outcome data, not waist circumference theater. Tirzepatide adds GIP agonism on top of GLP-1. In SURMOUNT-5, the first large head-to-head obesity trial of maximum tolerated tirzepatide versus maximum tolerated semaglutide over 72 weeks, mean weight change was about −20.2% with tirzepatide versus −13.7% with semaglutide, with a larger waist reduction as well.

Clinic preference: when an injectable is appropriate and available, tirzepatide (Mounjaro for diabetes, Zepbound for weight) is usually the first pick here. Coverage, supply, diabetes status, and prior GI intolerance still decide the real-world choice.

Goals worth writing before the first pen

Fat mass and waist, A1c or progression to diabetes, blood pressure, triglycerides, sleep apnea symptoms, knee load, and how stairs feel beat a seven-day scale average. Under appetite suppression, protein and progressive resistance training are not optional. Lean mass falls with any large deficit. Protecting it is part of the prescription. Define success at 12 and 24 weeks, including what side effect burden is acceptable, before celebrating week two.

Common adverse effects, said plainly

Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and early satiety that becomes food noise is gone and so is dinner are the daily reality of titration. Most are mild to moderate and cluster during dose escalations. Slow the climb. Smaller meals. Less alcohol and heavy fat. Hold the dose through gastroenteritis or dehydration. Gallstones rise with rapid loss and with slowed biliary motility. Hair shedding after large losses is usually the energy deficit, not a mysterious toxin, but severe fatigue still needs a look for iron, thyroid, sleep apnea, and too-aggressive intake restriction.

Pancreatitis: label caution, trial nuance

Labels still warn about pancreatitis, and severe persistent abdominal pain with or without vomiting remains a stop-and-evaluate rule. Large placebo-controlled programs for the modern agents have not shown a clear excess of adjudicated acute pancreatitis, and lipase often rises without predicting clinical disease. The practical middle path: do not ignore a pancreatitis picture, use caution after prior pancreatitis, and remember that gallstones from rapid loss can be the actual pathway to pancreatic inflammation. Ordinary titration nausea is not pancreatitis.

Medullary thyroid cancer: rats, MEN2, and honesty

Boxed warnings about thyroid C-cell tumors come from rodent biology that does not map cleanly onto human C cells. Personal or family history of medullary thyroid carcinoma and MEN2 remain hard contraindications. Population data have not produced a human MTC epidemic that matches the rat story. Counsel on neck mass, dysphagia, and hoarseness. Do not use the boxed warning as a scare tactic against every eligible adult, and do not pretend the label is optional.

Oral options, including Foundayo

Needle refusal is a real barrier. Oral semaglutide (Rybelsus) works for diabetes when people actually keep the fasting and water rules; many do not. Foundayo (orforglipron), approved in 2026, is a once daily small-molecule GLP-1 receptor agonist for chronic weight management that can be taken with or without food. In the label trials, 72-week mean weight change in adults without diabetes ran roughly −7% to −11% across doses versus about −2% on placebo, with smaller absolute losses in the type 2 diabetes trial. That is clinically meaningful and logistically easier than an injection for some people. It is also not SURMOUNT-5 tirzepatide. Set expectations: oral convenience is not the same magnitude as dual-agonist injectable efficacy in the current datasets. Do not stack Foundayo with another GLP-1 agonist.

Stopping, regain, and why maintenance is the point

The fantasy is lose it, stop it, keep it. SURMOUNT-4 and the STEP 1 extension keep killing that story. After substantial loss on therapy, switching to placebo produces large regain for most people within a year, and cardiometabolic improvements move backward with the weight. Continuing therapy holds the line. Obesity pharmacotherapy behaves more like blood pressure medicine than like a six-week antibiotic. Attempts to wean should be planned: protein and training locked in, sleep protected, and a regain threshold that triggers restart without shame. Maintenance is often the lowest effective dose that holds weight and labs without intolerable side effects, not eternal maximum titration.

Clinic sentence: if stopping is the plan, define what regain would mean before the first dose. If maintenance is the plan, titrate to the lowest dose that holds the benefit.

Who should slow down or choose another path

MTC or MEN2 history, pregnancy or near-term pregnancy plans, serious hypersensitivity, and major active GI disease that titration would worsen change the plan. Active gallbladder symptoms, prior pancreatitis, proliferative retinopathy that needs ophthalmology input, and eating disorder history deserve a slower, more supervised route or a different tool. Compounded lookalikes and unsupervised online pens remain a separate safety problem.

The decision, compressed

Start when obesity or overweight with comorbidity is the disease being treated, the person can tolerate titration, monitoring is available, and everyone agrees the likely path includes maintenance. Prefer tirzepatide among injectables when access allows, because SURMOUNT-5 put a number on the dual-agonist advantage. Consider Foundayo or other orals when injections are the barrier and expectations match the oral effect sizes. Respect the rodent MTC contraindications without turning them into folklore. Treat pancreatitis symptoms seriously even while recognizing that modern trial data have not shown a clear excess. Plan for regain if the drug stops. That is the honest visit.

Limits of this briefing

This article does not choose your drug, negotiate prior auth, or calculate your calories. Key references for clinicians: SURMOUNT-5 (NEJM 2025); SURMOUNT-4 and related withdrawal analyses; STEP 1 extension; SELECT; Foundayo (orforglipron) prescribing information; FDA labels for tirzepatide and semaglutide.